New hope for Crohn's scarring? early safety trial completed
NCT ID NCT07118878
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 29 times
Summary
This study tested a new medicine called AGMB-129 in 30 healthy adults to see if it is safe and how the body processes it. The drug is being developed to treat scarring and blockages in the gut caused by Crohn's disease, for which there are no approved treatments yet. This early-phase trial helps determine the right dose for future studies in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROSTENOTIC CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SGS Belgium
Edegem, Belgium
Conditions
Explore the condition pages connected to this study.